LOS ANGELES, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB)
announced today that it completed its acquisition of GEDi Cube Intl Ltd.
("GEDiCube"). Renovaro, which means renew, combines the power of the AI Health
Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech
platform of Renovaro Biosciences to accelerate precision, personalized medicine,
and a new era in healthcare innovation. The two subsidiaries will be under the
parent organization, which was renamed Renovaro Inc.
The combination will see Renovaro's existing CEO, The Hon. Mark Dybul, MD,
leading Renovaro Inc., with GEDiCube's CEO, Coen van Kalken, MD PhD, becoming
the Managing Director and President of GEDiCube and Dr. Francois Binette,
currently, Executive Vice-President and COO of Renovaro, becoming the Managing
Director and President of Renovaro Biosciences.
"We believe this combination marks a significant milestone in the journey of
personalized medicine," said Dr. Dybul. "Together, we believe that we are poised
to redefine healthcare delivery, making it more precise, effective, and
accessible."
Dr. van Kalken added, "The fusion of AI and biotech opens up new horizons in
healthcare. We have been advancing strategic partnerships with leading academic
centers and technology companies while working to expand our existing
relationship with NVIDIA. We believe our combined capabilities will help to
accelerate both the ability to detect and treat cancer and other diseases."
About GEDiCube
At GEDiCube, we are committed to the early detection of cancer, to intervene at
a stage where treatment can be most effective. We have developed an award-
winning AI Technology that significantly accelerates early cancer detection and
diagnosis at an early stage and its recurrence via liquid biopsy. Our platform,
"The Cube," brings together proprietary artificial intelligence (AI/ML)
technology and algorithms, multi-omics, multi-modal data, and the expertise of a
carefully selected multidisciplinary team to accelerate precision medicine and
enable breakthrough changes in cancer care. As of this morning, GEDiCube will
operate under its new name, RenovaroCube.
About Renovaro
Renovaro aims to accelerate precision, personalized medicine for longevity
powered by mutually reinforcing AI and biotechnology platforms for early
diagnosis, better-targeted treatments, and drug discovery. Renovaro includes
RenovaroCube and Renovaro Biosciences. Renovaro Biosciences is an advanced cell-
gene-immunotherapy company. Its lead candidate product is a therapeutic vaccine
targeting cancers which are difficult to treat including pancreatic and
potentially HNC, triple-negative breast cancer, and advanced liver cancer.
However, the vaccine could potentially work for all solid tumors and chronic
infectious diseases such as HIV and Hepatitis B Virus.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are
forward-looking statements. These statements are only predictions based on
current information and expectations and involve a number of risks and
uncertainties, including but not limited to the success or efficacy of our
pipeline. All statements other than historical facts are forward-looking
statements, which can be identified by the use of forward-looking terminology
such as "believes," "plans," "expects," "aims," "intends," "potential," or
similar expressions. Actual events or results may differ materially from those
projected in any of such statements due to various uncertainties, including as
set forth in Renovaro's most recent Annual Report on Form 10-K and its
definitive proxy statement related to the acquisition of GEDi Cube Intl Ltd.
filed with the SEC. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. All forward-
looking statements are qualified in their entirety by this cautionary statement,
and Renovaro Inc. undertakes no obligation to revise or update this press
release to reflect events or circumstances after the date hereof.
Contact Information:
ir@renovarobio.com (mailto:ir@renovarobio.com)
Source: Renovaro Bioscience
Â